首页> 外文OA文献 >MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

【2h】

MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

机译：MA07.02从ALK阳性非小细胞肺癌中的alectimib阶段的第2阶段NP28761研究的疗效和安全数据更新了疗效和安全数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
D. Ross Camidge; Shirish Gadgeel; Sai-Hong Ou; Leena Gandhi; Gregory Riely; Jeremy Cetnar; Howard West; Mark Socinski; Alberto Chiappori; Tarek Mekhail; Bo Chao; Hossein Borghaei; Kathryn Gold; Walter Bordogna; Bogdana Balas; Johannes Noe; Sophie Golding; Ali Zeaiter; Alice Shaw;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer [J] . D. Ross Camidge, Shirish Gadgeel, Sai-Hong Ou, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：MA07.02从ALK阳性非小细胞肺癌中的alectimib阶段的第2阶段NP28761研究的疗效和安全数据更新了疗效和安全数据
2. MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer [J] . D. Ross Camidge, Shirish Gadgeel, Sai-Hong Ou, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：MA07.02从ALK阳性非小细胞肺癌中的alectimib阶段的第2阶段NP28761研究的疗效和安全数据更新了疗效和安全数据
3. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer [J] . Ou Sai-Hong Ignatius, Gadgeel Shirish M., Barlesi Fabrice, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2020,第1期

机译：从Alk阳性非小细胞肺癌中粘合来自邻接期II研究（NP28673和NP28761）的总存活和安全数据
4. Data Analysis and Network Study of Non-small-cell Lung Cancer Biomarkers [C] . Koel De Mukherjee, Aman Vats, Deepshikha Ghosh, International Conference on Computational Intelligence . 2020

机译：非小细胞肺癌生物标志物的数据分析与网络研究
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies [O] . Shirish Gadgeel, Alice T Shaw, Fabrice Barlesi, 2019

机译：II期NP28673和NP28761阶段接受伊莱替尼治疗的晚期间变性淋巴瘤激酶（ALK）-阳性非小细胞肺癌（NSCLC）患者的反应时间
7. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. [O] . Yang, JC-H, Ou, S-HI, De Petris, L, 2017

机译：来自alectinib的关键性II期研究（Np28673和Np28761）在aLK阳性非小细胞肺癌中的汇总系统功效和安全性数据。

MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅